REGISTRATION AND ENROLLMENT PLAN 4.1 Registration Procedure Patients who are considered c andidates for the study will first be evaluated for eligibility by one of the principal investigators, co -investigators, or the research nurse. After screening for eligibility , patients who are eligible to participa te in the trial must be registered with the Sidney Kimmel Comprehensive Cancer Center (SKCCC) according to the instructions below. A record of patients who fail to meet entry criteria ( i.e., screen failures) will also be maintained. R egistration must be completed before beginning any study- related activities. To initiate regist ration at SKCCC , study personnel should forward copies of the signed informed consent form (with embedded research authorization/HIPAA form ), the institutional registration form, plus any required pathology information/ laboratory tests to the project manager by fax or email . Once eligibility is confirmed , each subject will be assign ed a unique patient study identification number . Treatment must not commence until the patient has received his identification number. Prior to protocol enrollment and initiation of treatment, subjects must sign and date an IRB - approved consent form. Authorized study personnel should fully explain the scope of the study to each patient before obtaining informed consent. Patients should be advised of any known risks inherent in the planned treatments/ procedures, any alternative treatment options, their right to withdraw from the study at any time and for any reason, and their right to privacy . When obtaining informed consent, study personne l should: f irst, confirm that the patient has received and has had time to read the informed consent form (including the research authorization/HIPAA form ); next, confirm eligibility as defined in Sections 3.2 and 3.3 (inclusion and exclusion criteria); and finally , obtain dated and si gned informed consent. A copy of the signed informed consent should be supplied to the project manager. To register a patient, the following documents must be completed and faxed (410 -614-7287) or emailed ( hcao7@jhmi.edu ) to the study coordinator , Harry Cao : • signed patient consent form • institutional registration form • copies of the prostate cancer pathology report and baseline laboratory studies including CBC with differential, liver and kidney function tests . Other materials may also be sent if considered pertinent for confirming patient eligibility. The principal investigator and/or other authorized study personnel will then review these documents to confirm eligibility. To complete the regis tration process, the project manager will assign a patient study number (i.e., protocol patient number). This number is unique to the patient and must be written on all data and correspondence for the patient. The project manager will also register the patient with SKCCC’s Clinical Research Office (CRO) . 4.2 Expected Enrollment A total of 32 patients (16 in each arm) will be included in this study. The first patients are expected to be enrolled in October 2012, once the protocol has been approved by the IRB . With an estimated enrollment rate of 4 patients per month, a ccrual is expected to be completed in 8 months . 4.3 Study Centers This is a single -institution study that will be conducted only at Johns Hopkins through a collaboration between the Brady Urological Institute and the Sidney Kimmel Comprehensive Cancer Center . Androgen suppression with prostate GVAX and cyclophosphamide J1 265 Johns Hopkins University 23 of 68 J1265 PROT (Vers) 1.4 113012 4.4 Recruitment Subjects will be recruited from the outpatient facilities of th e Brady Urological Institute, and from the outpatient Multidisciplinary Prostate Cancer Clinic of the SKCC C. Patients will not receive payment or reimbursement for participation.